Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar 1;6(1):102.
doi: 10.1038/s41392-021-00490-x.

COVID-19: cross-immunity of viral epitopes may influence severity of infection and immune response

Junaid Kashir  1   2 , Khaled AlKattan  1 , Ahmed Yaqinuddin  3
Affiliations
Comment

COVID-19: cross-immunity of viral epitopes may influence severity of infection and immune response

Junaid Kashir et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Representative indicators of the findings by Shrock et al., suggesting significant overlap between SARS-CoV-2 proteins with other coronaviruses in human patients. a Box plots illustrating the number of peptide hits from the indicated coronaviruses in confirmed COVID-19 patients and pre-COVID-19 era controls (negative for SARS-CoV-2). Cross-reactivity toward SARS-CoV-2 peptides was observed in pre-COVID-19 era samples, while COVID-19 patients also exhibited cross-reactivity with other common hCoVs, SARS-CoV, and MERS-CoV. b Bar graphs depicting the average number of peptides derived from SARS-CoV-2, SARS-CoV, and each of the four most common hCoVs significantly enriched per sample following IgG immunoprecipitation in the experiments of Shrock et al. The ORF1 region of SARS-CoV-2 exhibited greatest comparative matches between patients diagnosed with COVID-19 versus those that tested negative, indicating a potentially large degree of overlap between previous CoV and SARS-CoV-2 infection, whereby previous CoV perhaps reduced the severity of SARS-CoV-2 infection. Figure adapted from Shrock et al., with permission
See this image and copyright information in PMC

Comment on

  • Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.
    Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, Robinson ML, Sie BM, Li MZ, Chen Y, Logue J, Zuiani A, McCulloch D, Lelis FJN, Henson S, Monaco DR, Travers M, Habibi S, Clarke WA, Caturegli P, Laeyendecker O, Piechocka-Trocha A, Li JZ, Khatri A, Chu HY; MGH COVID-19 Collection & Processing Team; Villani AC, Kays K, Goldberg MB, Hacohen N, Filbin MR, Yu XG, Walker BD, Wesemann DR, Larman HB, Lederer JA, Elledge SJ. Shrock E, et al. Science. 2020 Nov 27;370(6520):eabd4250. doi: 10.1126/science.abd4250. Epub 2020 Sep 29. Science. 2020. PMID: 32994364 Free PMC article.

References

    1. Shrock E, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020;370:eabd4250. doi: 10.1126/science.abd4250. - DOI - PMC - PubMed
    1. Yaqinuddin A. Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities. Med. Hypotheses. 2020;144:110049. doi: 10.1016/j.mehy.2020.110049. - DOI - PMC - PubMed
    1. João C, Negi VS, Kazatchkine MD, Bayry J, Kaveri SV. Passive serum therapy to immunomodulation by IVIG: a fascinating journey of antibodies. J. Immunol. 2018;200:1957–1963. doi: 10.4049/jimmunol.1701271. - DOI - PubMed
    1. Liu X, Cao W, Li T. High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects. Front. Immunol. 2020;11:1660. doi: 10.3389/fimmu.2020.01660. - DOI - PMC - PubMed
    1. Chumakov K, Benn CS, Aaby P, Kottilil S, Gallo R. Can existing live vaccines prevent COVID-19? Science. 2020;368:1187–1188. doi: 10.1126/science.abc4262. - DOI - PubMed

Publication types

Substances